We advised CARsgen Therapeutics on its IPO and HKEX listing

Davis Polk advised CARsgen Therapeutics Holdings Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and a global offering in reliance on Rule 144A and Regulation S. The gross proceeds from the offering amounted to HK$3.1 billion (US$400 million) prior to any exercise of the over-allotment option.

CARsgen Therapeutics is a biopharmaceutical company with operations in China and the United States focused on innovative CAR-T cell therapies for the treatment of hematological malignancies and solid tumors. As a key player in the field of CAR-T cell therapies, CARsgen Therapeutics has obtained seven IND clearances for CAR-T therapies in China, the United States and Canada.

The Davis Polk corporate team included partners Li He and Yang Chu, counsel Xuelin (Steve) Wang and Lillian Lian, registered foreign lawyer Jennifer Liu and associate Edwin Lee. Associate Omer Harel provided tax advice. Counsel Sarah E. Kim and associate Leon E. Salkin provided 1940 Act advice. Members of the Davis Polk team are based in the Hong Kong, Beijing, London and New York offices.

Copy link to share post